drugset / Trial / NCT02405598

Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease

NCT02405598

Phase 4 Completed 14 enrolled National Taiwan University Hospital
NaSingle-groupOpen-labelTreatment

Summary

evaluate if beta 2-adrenergic agonist can have adjuvant effect to patients with infantile-onset Pompe disease under enzyme replacement therapy

Timeline

Start
2013-10
Primary completion
2015-07
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Salbutamol Unknown 0.2 mg/kg
Subject Salbutamol Unknown 4 mg
Subject Salbutamol Unknown 8 mg